Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 10/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 10/20 | 0.52 |
| ▸ | NQO2 | P16083 | 8/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.51 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2466357 | 0.87 | MTNR1A (0.62) | PDE4APDE4BPDE4CPDE4DMTNR1A | |
| SCHEMBL8501324 | 0.87 | MTNR1A (0.62) | PDE4APDE4BPDE4CPDE4DMTNR1A | |
| SCHEMBL4427914 | 0.87 | MTNR1A (0.62) | PDE4APDE4BPDE4CPDE4DMTNR1A | |
| SCHEMBL9630654 | 0.83 | MTNR1A (0.65) | PDE4APDE4BPDE4CPDE4DMTNR1A | |
| SCHEMBL11602838 | 0.80 | MEN1 (0.57) | MTNR1AMTNR1BNQO2KDM1AMAOA | |
| SCHEMBL5484314 | 0.79 | ACHE (0.60) | PDE4APDE4BPDE4CPDE4DMTNR1A | |
| SCHEMBL4017021 | 0.79 | MTNR1A (0.54) | MTNR1AMTNR1BNQO2PDE10A | |
| SCHEMBL11009151 | 0.78 | MTNR1A (0.55) | PDE4APDE4BPDE4CPDE4DMTNR1A | |
| SCHEMBL2825083 | 0.78 | MTNR1A (0.54) | MTNR1AMTNR1BNQO2 | |
| Hydrochloric Acid SCHEMBL9630772 | 0.78 | ACHE (0.63) | PDE4APDE4BPDE4CPDE4DMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021450-A1 | Indanylamino uracils and their use as antioxidants and neuroprotectants | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2007-01-25 | — | — | US | disclosed |
| WO-2006020070-A2 | INDANYLAMINO URACILS AND THEIR USE AS ANTIOXIDANTS AND NEUROPROTECTANTS | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021450-A1 | Indanylamino uracils and their use as antioxidants and neuroprotectants | OGG1, CBR3, C1R | PDE4A 3228/4885PDE4B 3410/4885PDE4C 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.